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Diabetes mellitus is increasing worldwide, resulting from the interaction of obesity,
inflammation, and hyperglycemia. Activated immunity and cytokine production lead to
insulin resistance and other components of the metabolic syndrome, establishing the link
between diabetes and atherosclerosis. Hyperglycemia-induced endothelial dysfunction is
mediated by increased oxidative stress, a promoter of adventitial inflammation and vasa
vasorum neovascularization in experimental models of diabetic atherosclerosis. Recent studies
have documented increased inflammation, neovascularization, and intraplaque hemorrhage in
human diabetic atherosclerosis. This inflammatory microangiopathic process is independently
associated with plaque rupture, leading to coronary thrombosis. Tissue factor, the most potent
trigger of the coagulation cascade, is increased in diabetic patients with poor glycemic control.
Circulating tissue factor microparticles are also associated with apoptosis of plaque macro-
phages, closing the link among inflammation, plaque rupture, and blood thrombogenicity.
High-density lipoproteins, responsible for free cholesterol removal, are reduced in patients
with insulin resistance and diabetes. High-density lipoprotein therapy leads to a significant
decrease in plaque macrophages and increase in smooth-muscle cells. These beneficial effects
may be responsible for coronary plaque stabilization in patients treated with recombinant
Apolipoprotein A-I Milano/phospholipid complex. Finally, peroxisomal proliferator-
activated receptors (PPARs) are now considered the nuclear transcriptional regulators of
atherosclerosis. Three subfamilies, including PPAR-alpha, -delta, and -gamma, have been
identified with crucial roles in lipid metabolism, plaque inflammation, expression of adhesion
molecules and cytokines, and regulation of matrix metalloproteinases. Multiple experimental
studies have documented plaque stabilization with PPAR-gamma agonists, a group of
medications holding great promise in the treatment of diabetes atherosclerosis. (J Am Coll
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.07.060Cardiol 2004;44:2293–300) © 2004 by the American College of Cardiology Foundation
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(iabetes mellitus affects 150 million people worldwide and
lose to 20 million in the U.S. The prevalence of diabetes
mong U.S. adults has increased by 40% in the past decade,
nd is expected to increase by 165% between 2000 and 2050
1,2). Furthermore, one-third of the population born in
000 will develop diabetes, with up to 30% reduction in life
xpectancy, mostly related to atherosclerosis, which is re-
ponsible for up to 80% of all deaths among North Amer-
can diabetic patients (3,4). Mortality from myocardial
nfarction in patients with diabetes is markedly higher than
n nondiabetic patients (5,6). As a result, diabetes mellitus
mposes a large economic burden on society, estimated to be
s much as $100 billion per year in the U.S. alone (7).
This review focuses on the pathophysiology of diabetic
therosclerosis, from the metabolic syndrome to advanced
isease, plaque rupture, and coronary thrombosis. Inflam-
ation, neovascularization, apoptosis, and the hypercoagu-
From the *Zena and Michael Wiener Cardiovascular Institute, Mount Sinai School
f Medicine, New York, New York; and the †Gill Heart Institute, University of
entucky, Lexington, Kentucky. The work reported in this review has been partially
upported by grants from the National Institutes of Health Specialized Centers of
esearch HL54469 and the National Heart, Lung, and Blood Institute HL61801 (to
r. Fuster).(
Manuscript received April 2, 2004; revised manuscript received May 20, 2004,
ccepted July 5, 2004.able state associated with the disease are reviewed. Finally,
ovel experimental therapies are presented.
ETABOLIC SYNDROME
reviously known as the prediabetes state, the metabolic
yndrome is characterized by at least two of the following
onditions: abdominal obesity, insulin resistance (elevated
asting glucose), hypertension, dyslipidemia (elevated tri-
lyceride and decreased high-density lipoprotein [HDL]
holesterol levels), and microalbuminuria (8). Age-adjusted
revalence of this syndrome in the U.S. reaches 23.7% of the
otal population and up to 43.5% in people older than 60
ears (Fig. 1). According to 2000 census data, about 47
illion U.S. residents have the metabolic syndrome, corre-
ating with the 61% increase in the incidence of obesity in
he last decade (9,10).
Epidemiologic studies have elucidated the importance of
he metabolic syndrome in diabetes mellitus. When both
onditions co-exist, as commonly observed, the prevalence
f coronary disease reaches 19.2% of the population. How-
ver, in the absence of the metabolic syndrome, the preva-
ence of coronary disease in patients with diabetes is low
7.5%), similar to the population without diabetes (8.7%)
Fig. 2) (11).
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Pathogenesis of Diabetes Atherosclerosis December 21, 2004:2293–300Innate immunity and inflammation play a role in the
evelopment of insulin resistance and the development of
iabetes mellitus. Since the hypothesis was proposed in
997, at least 12 studies have shown that circulating markers
f inflammation, acute-phase reactants, or interleukin-6
the major cytokine mediator of the acute-phase response)
re strong predictors of the development of type 2 diabetes
12). Thus, the pathophysiology of insulin resistance, the
etabolic syndrome, and atherosclerosis may have a com-
on proximal inflammatory basis (Fig. 3).
ARLY STAGES OF DIABETIC ATHEROSCLEROSIS
ive major molecular mechanisms have been implicated in
yperglycemia-induced endothelial damage: activation of
rotein kinase C isoforms via de novo synthesis of the lipid
econd messenger diacylglycerol, increased hexosamine
athway flux, increased advanced glycation end product
AGE) formation, increased polyol pathway flux, and acti-
ation of the proinflammatory nuclear transcription factor
uclear factor-kappa B (13,14). All of these mechanisms are
ndependently associated with overproduction of superoxide
y the mitochondrial electron transport chain (15). As a
esult, hyperglycemia-induced formation of reactive oxygen
pecies (ROS) may lead to endothelial dysfunction, decreas-
ng the bioavailability of nitric oxide and prostacyclin,
ncreasing the synthesis of vasoconstrictor prostanoids and
ndothelin, and promoting atherosclerotic plaque formation
16). This attractive hypothesis needs further testing to
igure 1. Age-specific prevalence of the metabolic syndrome among 8,814
.S. adults aged at least 20 years of age, by gender, National Health and
Abbreviations and Acronyms
AGE  advanced glycation end product
HDL  high-density lipoprotein
MMP  matrix metalloproteinase
PPAR  peroxisomal proliferator-activated receptor
ROS  reactive oxygen species
TF  tissue factorc
utrition Examination Survey III, 1988 to 1994. Modified with permis-
ion from Zimmet et al. (8).ompletely elucidate the role of ROS in the pathogenesis of
iabetic atherosclerosis.
Diabetic endothelial dysfunction is also expressed by
ncreased vascular permeability related to hyperglycemia-
nduced ROS production occurring as early as two weeks
fter the onset of diabetes (17). Recently, endothelial
ysfunction was documented by decreased flow-mediated
rachial artery dilation in children with diabetes mellitus,
eading to early atherosclerosis, as evidenced by increased
arotid intimomedial thickness (18). Furthermore, diabetes-
nduced microvascular permeability is responsible for ex-
ression of the well-known endothelial mitogen vascular
ndothelial growth factor, the main promoter of angiogen-
sis and neovascularization responsible for diabetic mi-
roangiopathy (19,20).
DVANCED STAGES OF DIABETIC ATHEROSCLEROSIS
nsulin resistance is associated with macrophage upregula-
ion of CD36 protein with increased uptake of oxidized
ow-density lipoprotein in experimental obesity (21). Hy-
erglycemia increases macrophage matrix metalloproteinase
MMP) expression (22), which is up-regulated in human
broblasts from patients with diabetes mellitus (23). In
ddition, MMP-2 is marker for microangiopathy in chil-
ren with type 1 diabetes (24), suggesting a pivotal role for
acrophages in the pathogenesis of diabetic atherosclerosis.
evertheless, the absence of a reproducible animal model of
therosclerosis in type II diabetes mellitus may limit these
bservations.
Plaque composition may be different in patients with
iabetes. Macrophage infiltration and thrombus formation
re increased in advanced coronary plaques from diabetic
atients with unstable angina (Fig. 4) (25). Recent autopsy
tudies have confirmed this observation (26).
New structural and functional features characterizing
iabetic atherosclerosis have been recently identified, in-
igure 2. Age-adjusted prevalence of coronary heart disease (CHD) in the
.S. population over 50 years of age categorized by presence of metabolic
yndrome (MS) and diabetes mellitus (DM). Combinations of metabolic
yndrome and diabetes mellitus status are shown. Reprinted with permis-
ion from Alexander et al. (11).luding adventitial inflammation and vasa vasorum neovas-
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December 21, 2004:2293–300 Pathogenesis of Diabetes Atherosclerosisularization leading to intraplaque hemorrhage, macrophage
ctivation, and lipid core expansion evolving into high-risk
therosclerotic lesions. The mechanistic role of diabetic-
nduced oxidative stress in adventitial inflammation and
eovascularization provides new pathogenic links between
yperglycemia and atherosclerosis.
DVENTITIAL INFLAMMATION
dventitial inflammation is frequently observed surround-
ng vasa vasorum in ruptured plaques from patients with
nstable angina and acute myocardial infarction (27,28).
o evaluate diabetes-induced oxidative stress and adven-
itial inflammation, Zhang et al. (29) documented in-
igure 3. Several factors such as altered nutrition, inactivity, age, fetal met
mmune system. Cytokine production leads to insulin resistance, type 2 dia
ctivated innate immunity is a possible common antecedent of both type
actor-alpha. Modified with permission from Pickup (12).
igure 4. (Left) Increased percent macrophage area in coronary tissue fro
Right) Photomicrographs of coronary atherectomy tissue immunostained
n coronary tissue from a patient with diabetes mellitus (A) than in coronary tis
oreno PR, et al. Circulation 2000;102:2180–4.reased cytokines (interleukin-6 and tumor necrosis factor-
lpha), chemokines (macrophage chemotactic protein-1),
nd adhesive molecules in adventitial fibroblasts from
treptozotocin-induced diabetic swine. Oxidative stress was
esponsible for this inflammatory response mediated by
GE-induced activation of the transcriptional factor nu-
lear factor-kappa B in coronary adventitial fibroblasts (29),
roviding a mechanistic link between diabetes, oxidative
tress, and adventitial inflammation.
Adventitial inflammation can also extend into the tunica
edia, inducing atrophy and fibrosis. Increased content of
acrophage-derived MMP-2 and -9 within the intimome-
ial interface of advanced plaques has been described
30,31). This increased activity of MMP is associated with
programming, and genetic propensity are known activators of the innate
, and other components of the metabolic syndrome, such as dyslipidemia.
betes and atherosclerosis. IL-6  interleukin-6; TNF  tumor necrosis
tients with diabetes mellitus versus tissue from patients without diabetes.
antihuman pan-macrophage antibody. Larger macrophage content is seenabolic
betesm pa
withsue from a patient without diabetes (B). Reprinted with permission from
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Pathogenesis of Diabetes Atherosclerosis December 21, 2004:2293–300isruption of the internal elastic lamina, an independent
redictor of plaque rupture (Fig. 5) (32).
Adventitial inflammation is also associated with vasa
asorum neovascularization leading to red blood cell extra-
asation, foam cell formation, and lipid core expansion
33,34).
ASA VASORUM NEOVASCULARIZATION
eovascularization of the vessel wall is a consistent feature
f atherosclerotic plaque development (35). Neovessels may
erve as a port of entry to blood-derived cells, providing
utrients to aerobic cells like macrophages and smooth-
uscle cells. Vasa vasorum neovascularization is present
ithin the first two to four weeks of hypercholesterolemic
iet, preceding endothelial dysfunction (36). Furthermore,
eovessels are involved in plaque hemorrhage and the
igure 5. Rupture of the internal elastic lamina (IEL). Photomicrograph
f advanced aortic diabetic atherosclerosis illustrating an aggressive inflam-
atory pattern at the intimomedial junction. The continuity of IEL (left
ide) is interrupted (right side) where multiple round-nuclei inflammatory
ells are observed, expanding the atherosclerotic process from the tunica
ntima into the tunica media (elastic trichrome stain). Courtesy of Dr.
-Raman Purushothaman (Mount Sinai Medical Center, New York, New
ork).
igure 6. Photomicrographs of microvessels identified by double-label
mooth-muscle actin (right). (A) Microvessels are labeled with blue chrom
ase of the plaque. (B) Tunica media microvessels are labeled with a purple chro
ith permission from Moreno PR, et al. Circulation 2004;110:2032–8.evelopment of symptoms in cerebrovascular disease, and
hey may play a role in plaque rupture (37,38).
The amount of neovascularization correlates with the
xtent of inflammatory cells (39). We recently evaluated
icrovessel and inflammatory cell content in complex ath-
rosclerosis. Macrophages, T-lymphocytes, and smooth-
uscle cells were defined as CD68, CD3, and alpha
ctin-positive cells, respectively (Fig. 6).
Total and regional microvessel densities were increased in
uptured plaques when compared with non-ruptured
laques (Fig. 7). Furthermore, microvessel density was
ncreased in lesions with inflammation, intraplaque hemor-
hage, and in thin-cap fibroatheromas. Microvessels at the
ase of the plaque independently correlated with plaque
upture, suggesting a contributory role for microvessels in
laque instability (40,41).
Purushothaman et al. (42) recently studied microvessel
nd inflammatory cell content in 230 plaques from patients
ith diabetes mellitus. Ruptured plaques were excluded
rom this analysis. Microvessel content, macrophages/T-
ymphocyte cells, and intraplaque hemorrhage were all
ncreased in plaques from patients with diabetes mellitus.
hese differences in plaque composition may increase the
isk of plaque rupture in diabetic atherosclerosis. However,
ore studies are needed to confirm these observations.
ORONARY THROMBOSIS
iabetes is characterized by elevated concentrations of
rocoagulant factors, including fibrinogen, von Willebrand
actor, and factor VII, with decreased concentration of
ntithrombotic factors including antithrombin III and pro-
ein C (43). Arterial thrombosis is mediated by tissue factor
TF), the most potent trigger of the coagulation cascade
44). Rauch et al. (45) reported that polymorphonuclear
eukocytes might be involved in the transport of circulating
F to platelets by a CD15-dependent mechanism. Higher
evels of plasma TF antigen (46) and circulating TF-positive
icroparticles with procoagulant activity have been de-
nochemistry stain using CD34 and CD68/CD3 (left) and CD34 and
and macrophages/T lymphocytes are labeled with a red chromogen at theimmu
ogenmogen and the smooth-muscle cells with a brown chromogen. Reprinted
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December 21, 2004:2293–300 Pathogenesis of Diabetes Atherosclerosiscribed in patients with acute coronary syndromes (47).
allat and Tedgui (48) linked the apoptotic phenomena to
therothrombosis and to the production of TF. More
ecently, Hutter et al. (49) showed that apoptosis of plaque
acrophages co-localize with TF expression, suggesting a
otential pathogenic mechanism leading to increased plaque
hrombogenicity.
Tissue factor is increased in patients with diabetes mel-
itus (50). Recently, Sambola et al. (51) identified significant
eductions in TF activity and blood thrombogenicity in
iabetic patients with improved glycemic control. These
bservations highlight the concept of high-risk blood in the
athophysiology of diabetic atherosclerosis leading to coro-
ary thrombosis.
OVEL THERAPIES:
MPLICATIONS FOR PLAQUE REGRESSION
espite multiple advances, diabetes still remains a com-
lex and challenging chronic condition to treat. A variety
f therapeutic options, from lifestyle interventions and
ight glycemic control to a large number of pharmaco-
ogic agents, are available to attenuate diabetic athero-
clerosis. The Centers for Disease Control recently sum-
arized current strategies for diabetes prevention by
ifestyle intervention (52). Three large randomized trials
efinitively established that moderate weight loss through
iet and physical activity reduces the incidence of type 2
iabetes in high-risk persons by 40% to 60% over three to
igure 7. Error bars showing the mean (95% confidence interval) of micr
omparisons of microvessel content within plaque/shoulder, tunica media
uptured plaques are presented.our years (53–55). Furthermore, pharmacologic inter- aention with metformin (850 mg/day) reduced the inci-
ence of diabetes by 31% (55). In addition, the use of
amipril reduced the incidence of newly diagnosed dia-
etes by 34% in the Heart Outcomes Prevention Evalu-
tion (HOPE) trial (56).
For patients with established diabetes, control of blood
ressure and the use of aspirin and angiotensin-converting
nzyme inhibitors reduces cardiovascular events (57). Fur-
hermore, aggressive lipid-lowering therapy is now a cor-
erstone in the treatment of diabetes mellitus, reducing
ardiovascular events by 22% independent of baseline lipid
evels (58).
In addition to established therapy, two novel alternatives
re under active experimental and clinical investigation in
atients with atherosclerosis and diabetes mellitus. These
nclude HDL therapies and the peroxisomal proliferator-
ctivated receptors (PPARs).
DL
he HDLs are responsible for the removal of free choles-
erol from the blood. Low plasma levels of HDL are
ssociated with increased cardiovascular risk. Low levels of
DL are frequently seen in patients with insulin resistance,
rom the metabolic syndrome to overt diabetes mellitus.
adimon et al. (59,60) elegantly demonstrated the anti-
therogenic properties of HDL, reducing the number of
atty streaks and inducing disease regression in the rabbit
xperimental model. More recently, Rong et al. (61) evalu-
el content in non-disrupted and disrupted human atherosclerotic plaques.
ial, plaque base, and total neovessel numbers between non-ruptured andovessted the effects of HDL in advanced experimental athero-
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Pathogenesis of Diabetes Atherosclerosis December 21, 2004:2293–300clerosis. Diseased thoracic aortic segments from hypercho-
esterolemic apolipoprotein E-deficient mice were
ransplanted in the abdominal aorta of apolipoprotein
-deficient mice not expressing (plasma HDL cholesterol
pproximately 26 mg/dl) or expressing (HDL approxi-
ately 64 mg/dl) a human apolipoprotein AI transgene.
ice with high plasma HDL showed significant changes in
laque composition, with macrophage area reductions
80% and smooth-muscle cell area increases 300%.
hese dramatic changes in plaque composition may explain
he promising results in plaque regression documented by
ntravascular ultrasound in patients with coronary artery
isease after five weeks of recombinant apolipoprotein A-I
ilano/phospholipid complex (62).
Within the control of lipid modifying strategies, high-
esolution magnetic resonance imaging can provide mech-
nistic information to understand plaque regression in
umans. Corti et al. documented a decrease in plaque size in
oth carotid and aortic lesions without changes in luminal
rea after 12 months of aggressive lipid-lowering therapy
63). Longer follow-up showed a further decrease in plaque
ize along with a slight, but significant, increase in luminal
rea at 24 months (64). The same pattern for plaque
egression was documented by Nissen et al. (65) using
ystematic intravascular ultrasound in patients with coronary
rtery disease, suggesting a major role for aggressive lipid-
igure 8. Direct and indirect effects of peroxisomal proliferator-activated
ynthetic ligands induces metabolic changes that may limit inflammation
ajor vascular and inflammatory cells and PPAR regulation of relevant tar
nflammation and atherosclerosis. ABCA1  ATP-binding cassette transp
monocyte chemoattractive protein-1; VCAM1  vascular cell adhesionowering therapy in plaque stabilization. BEROXISOME PROLIFERATOR-
CTIVATED RECEPTORS (PPARS)
he PPARs are steroid hormone nuclear receptors that act
s ligand-activated transcription factors controlling the ex-
ression of specific target genes that in turn regulate a
ariety of cellular functions (66). The PPARs are considered
elevant nuclear transcriptional regulators of atherothrom-
osis (Fig. 8) (67). Three subfamilies have been described
ith different tissue distribution and effects: PPAR-alpha,
delta, and -gamma. The subfamily member PPAR-gamma
lays a central role in adipogenesis and lipid metabolism and
s highly expressed in endothelial cells, smooth-muscle cells,
ymphocytes, and macrophages. The PPAR-gamma activa-
ors may reduce plaque inflammation, inhibit expression of
dhesion molecules and cytokines, and reduce production of
MP (68).
Evidence indicates that PPAR-gamma activators can
ecrease thrombogenicity by reducing plasminogen activa-
or inhibitor-1 and fibrinogen concentrations to improve
brinolysis. In addition, PPAR-gamma activators may re-
uce production of endothelin-1, a potent vasoconstrictor
nd important atherogenic stimulus. Crucially, PPAR-
amma activators may reduce the lipid content of plaques by
nhancing reverse cholesterol transport and by up-
egulating the genes responsible for scavenger receptor class
ptors (PPARs). Peroxisomal proliferator-activated receptor activation by
therosclerosis indirectly. Alternatively, the expression of PPARs in most
nes in those cells raises the possibility that PPARs have a direct effect on
1; HDL  high-density lipoprotein; IFN  interferon gamma; MCP1
ecule-1. Reprinted with permission from Plutzky (67).rece
and a
get getype I human homologue, for adenosine triphosphate-
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December 21, 2004:2293–300 Pathogenesis of Diabetes Atherosclerosisinding cassette transporter-1, and for apolipoprotein A1,
hereby facilitating efflux of free cholesterol from the plaque
nd its transport to the liver. Using high-resolution mag-
etic resonance imaging, we recently observed plaque re-
ression and features of plaque stabilization in the athero-
clerotic rabbit model exposed to a new selective
PAR-gamma activator (69). The combination of statin
ith PPAR-gamma activator was superior to either medi-
ation alone, with decreased macrophage content and ma-
rix metalloproteinase activity and increased smooth-muscle
ell/collagen content in atherosclerotic lesions. Considering
he popularity of PPAR-gamma agonists in the treatment of
iabetes, these medications hold promise in the continuing
ght against atherosclerosis in patients with diabetes mel-
itus.
ONCLUSIONS
iabetic atherosclerosis is an aggressive disease responsible
or major health problems in modern society. The metabolic
yndrome, an inflammatory disease affecting 47 million U.S.
itizens, plays a pivotal role in atherosclerosis and requires
ajor attention for adequate treatment. New understanding
f the complex pathophysiology of atherosclerosis is consis-
ent with a disease involving all three layers of the vessel
all, with rupture of the internal elastic lamina and active
articipation of adventitial vasa vasorum responsible for
edia and plaque neovascularization. This microangio-
athic process is exaggerated in diabetes mellitus, associated
ith increased inflammation and intraplaque hemorrhage.
therosclerotic microvessels are increased in the tunica
edia and at the base of the plaque in advanced diabetic
laques. In addition, microvessels are also increased in
uptured plaques from patients with diabetes mellitus.
oronary thrombosis is mediated by the interactions of
ystemic procoagulant factors, which are up-regulated in
atients with diabetes mellitus. Tissue factor, the most
otent trigger of the coagulation cascade, is increased in
iabetics with poor glycemic control. Finally, novel thera-
ies, including HDL and PPAR agonists, hold great prom-
se for the future treatment of diabetic atherosclerosis.
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